Phagelux Inc. Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Nanjing China (2013)

Organization Overview

First Clinical Trial
2020
NCT04323475
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Phagelux Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

BACTELIDE (1 trial)

Drugs in Phase 1 Trials (1)

Phage Cocktail-SPK (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 1)

Infections (Phase 1)

Wound Infection (Phase 1)

Wounds and Injuries (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2